The randomised study with progression free survival (PFS) after 12 weeks as primary endpoint is designed to compare AXL1717 with docetaxel in patients with previously treated, locally advanced or metastatic NSCLC.
Axelar CEO Dr. Carl Harald Janson said AXL1717 showed positive impact in the difficult to treat patient population.
"The encouraging trial data provides a platform for the further development of AXL1717. I look forward to finalizing this trial and preparing for the next step in development," Janson added.
Preliminary data revealed similar AXL1717 rate of PFS as of docetaxel after 12 weeks.
Most frequent serious adverse events include cases with neutropenia in both treatment regimes.
The company finalised the trial to have 100 patients instead of the planned 140, on the basis of the interim data.